drugset / Trial / NCT00129168

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT00129168

Phase 1/2 Completed 100 enrolled Kanisa Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar in treating acute myeloid leukemia.

Timeline

Start
2005-08
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Zosuquidar Small molecule Intravenous
Background Cytarabine Small molecule
Background Daunorubicin Small molecule

Indications